Assessing the appropriate use of metformin in an inpatient setting and the effectiveness of two pharmacy-based measures to improve guideline adherence

Quality Management in Health Care

Volumn 18, Issue 1, 2009, Pages 71-76

  Scotton, David W ^a   Wierman, Heidi ^a   Coughlan, Ann ^b   Walters, Megan ^c   Kuhn, Celine ^a  

^a MAINE MEDICAL CENTER   (United States)

^b Miles Medical Group   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Electronic medical record; Guideline adherence; Lactic acidosis; Metformin; Quality improvement

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ARTICLE; COMPARATIVE STUDY; HEALTH CARE QUALITY; HOSPITAL PATIENT; HOSPITAL PHARMACY; HUMAN; MEDICAL AUDIT; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; INPATIENTS; MEDICAL AUDIT; METFORMIN; PHARMACY SERVICE, HOSPITAL; PROGRAM EVALUATION; RETROSPECTIVE STUDIES;

EID: 60549114583     PISSN: 10638628     EISSN: 15505154     Source Type: Journal    
DOI: 10.1097/01.QMH.0000344595.48510.cb     Document Type: Article

References (27)

1. Fantus G. Metformin's contraindications: needed for now. Can Med J. 2005;173(5):505-507.
2. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med. 2007;120(3, suppl 1):526-534.
3. Blonde L. Current challenges in diabetes management. Clin Cornerstone. 2005;7(suppl 3):S6-S17.
4. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diab Care. 1999;22(4):543-545.
5. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. Can Med Assoc J. 2005;173(5):502-504.
6. Wulffele MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diab Care. 2002;25(12):2133-2140.
7. Lusignan S. Trends in the prevalence and management of diagnosed type 2 diabetes; 1994-2001 in England and Wales. BMC Fam Pract. 2005;6(1). doi:10.1186/1471-2296-6-133.
8. Ebell M. Link between metformin and lactic acidosis? Am Fam Phys. 2004;70(11):2109-2110.
9. Chan NN, Brain HPS, Feher MD, et al. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diab Med. 1999;16:273-281.
10. Garber AJ. Metformin and vascular protection: a diabetologist's view. Diab Metab. 2003;29:6S113-6S116.
11. Millican S, Cottrell N, Green B. Do risk factors for lactic acidosis influence dosing of metformin. J Clin Pharm Ther. 2004;29:449-454.
12. Harvey B, Hickman C, Hinson G, et al. Severe lactic acidosis complicating metformin overdose successfully treated with high-volume venovenous hemofiltration and aggressive alkalinization. Crit Care Med. 2005;6:183-186.
13. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media - a dangerous combination? Clin Radiol. 1999;54:29-33.
14. Mosby's Drug Consult 2005. 15th ed. St Louis, MO: Elsevier Science; 2005.
15. Calabrese AT, Coley KC, DaPos SV, et al. Risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434-437.
16. Selby JV, Ettinger B, Swain BE, Brown JB. The first 20 months experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diab Care. 1999;22:38-43.
17. Emslie-Smith AM, Boyle DR, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diab Med. 2001;18:483-488.
18. Dunham DP, Baker D. Use of an electronic medical record to detect patients at high risk of metformin-induced lactic acidosis. Am J Health Syst Pharm. 2006;63:657-660.
19. Raebel A, Chester EA, Newsom EE, et al. Randomized trial to improve laboratory safety monitoring of ongoing drug therapy in ambulatory patients. Pharmacotherapy. 2006;26(5):619-626.
20. Smith DH, Perrin N, Feldstein A, et al. The impact of prescribing safety alerts for elderly persons in an electronic medical record. Arch Intern Med. 2006:166:1098-1104.
21. Lub R. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type II diabetes mellitus. Br J Clin Pharmacol. 2006;62(6):660-665.
22. Bekes C. Active learning. Crit Care Med. 2007;35(7):1785-1786.
23. Gross P, Greenfield S, Cretin S, et al. Optimal methods of guideline implementation. Med Care. 2001;39(8):II-85-II-92.
24. Keenan S. Moving beyond the numbers...the next step forward in improving patient care. Crit Care Med. 2007;35(3): 960-961.
25. Tinetti M, Baker D. Effect of disseminating of evidence in reducing injuries from falls. N Engl J Med. 2008;359(3):252-261.
26. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J. 1995;153(10):1423-1431.
27. Feifer C, Nemeth L. Different paths to high quality care: three archetypes of top-performing practice sites. Ann Fam Med. 2007;5(3):233-241.